First-line endocrine therapy by estrogen antagonism or suppression of estrogen achieves objective responses (ORs) and clinical benefit (CB) in around 30% and 50% of estrogen receptor-positive metastatic breast cancer patients,…
Estrogen Receptor–positive/HER-2 negative breast cancers represent a heterogeneous group of tumors. Luminal A and B tumor subtypes can be identified through immunohistochemical assessment of estrogen and progesterone receptor, Ki-67 and…
Duct carcinoma in situ (DCIS) is a common but non–life-threatening breast cancer. Four large prospective randomized trials comparing radiation therapy (RT) with none after breast-conservation surgery have all concluded that…
The development and wide acceptance of sentinel lymph node biopsy (SLNB) has profoundly affected the management of breast cancer. SLNB has spared the additional morbidity of axillary lymph node dissection…
Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy…
Harold J. Burstein, MD, PhD, Editor Breast cancer management has entered the era of personalized medicine. It is widely appreciated that breast cancers differ in their biology and treatment needs….
Osteosarcoma and chondrosarcoma are the 2 most common malignant bone tumors. This review discusses the clinicopathologic features, recent preclinical developments, and targets currently being or to be validated in the…
This article highlights the data currently available on the activity of targeted medical treatment in a subgroup of rare entities within soft tissue sarcomas, including inflammatory myofibroblastic tumor, alveolar soft…
Sarcomas are heterogeneous group of tumors that arise from tissues of mesenchymal origin. Current options for patients with advanced disease are limited, and only 2 drugs have been approved for…
The improvement in outcome for patients with localized and metastatic Ewing sarcoma since the development of cytotoxic chemotherapy remains one of the most profound advances in oncology and one of…
